QS Investors LLC lowered its position in shares of Zoetis Inc (NYSE:ZTS) by 39.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,879 shares of the company’s stock after selling 34,152 shares during the period. QS Investors LLC’s holdings in Zoetis were worth $3,737,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of ZTS. BlackRock Inc. boosted its stake in Zoetis by 3.8% in the fourth quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock valued at $2,772,498,000 after acquiring an additional 1,394,156 shares in the last quarter. Clearbridge Investments LLC boosted its stake in Zoetis by 3.9% in the fourth quarter. Clearbridge Investments LLC now owns 9,512,060 shares of the company’s stock valued at $685,249,000 after acquiring an additional 353,622 shares in the last quarter. Brown Advisory Inc. boosted its stake in Zoetis by 2.1% in the fourth quarter. Brown Advisory Inc. now owns 7,207,114 shares of the company’s stock valued at $519,200,000 after acquiring an additional 149,095 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Zoetis by 1.5% in the third quarter. Janus Henderson Group PLC now owns 5,893,853 shares of the company’s stock valued at $375,792,000 after acquiring an additional 84,767 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Zoetis by 4.7% in the fourth quarter. Wells Fargo & Company MN now owns 5,313,643 shares of the company’s stock valued at $382,795,000 after acquiring an additional 238,061 shares in the last quarter. Hedge funds and other institutional investors own 92.35% of the company’s stock.
Zoetis stock traded down $2.55 during mid-day trading on Friday, reaching $80.97. The company had a trading volume of 2,752,329 shares, compared to its average volume of 2,550,576. Zoetis Inc has a 1 year low of $52.36 and a 1 year high of $85.73. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. The stock has a market cap of $39,291.02, a PE ratio of 33.74, a price-to-earnings-growth ratio of 1.81 and a beta of 0.96.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period last year, the company posted $0.47 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. sell-side analysts forecast that Zoetis Inc will post 3.05 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.62%. Zoetis’s dividend payout ratio (DPR) is 20.83%.
In other news, EVP Roxanne Lagano sold 35,663 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares of the company’s stock, valued at approximately $4,044,437.38. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Heidi C. Chen sold 37,453 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The disclosure for this sale can be found here. Over the last three months, insiders have sold 112,952 shares of company stock valued at $9,219,843. Corporate insiders own 0.31% of the company’s stock.
ZTS has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price objective for the company. in a research note on Saturday, January 13th. Bank of America upped their price objective on shares of Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday, February 16th. Craig Hallum restated a “buy” rating and issued a $85.00 price objective (up previously from $77.00) on shares of Zoetis in a research note on Tuesday, January 2nd. Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Finally, Morgan Stanley downgraded shares of Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 price objective for the company. in a research note on Monday, March 19th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $80.94.
TRADEMARK VIOLATION WARNING: “Zoetis Inc (NYSE:ZTS) Shares Sold by QS Investors LLC” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/qs-investors-llc-sells-34152-shares-of-zoetis-inc-zts.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.